Development of viral oncolytic agent using mammalian orthoreovirus with improved infectivity

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19138
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Virology
• Research Institution: Osaka University
• Principal Investigator: KANAI YUTA 大阪大学, 微生物病研究所, 助教 (80506501)
• Co-Investigator(Renkei-kenkyūsha): Kobayashi Takeshi 大阪大学, 微生物病研究所, 准教授 (90324847) ; Kawagishi Takahiro 大阪大学, 微生物病研究所, 特任研究員 (90800029)
• Research Collaborator: Matsuura Yoshiharu 大阪大学, 微生物病研究所, 教授 (50157252)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: レオウイルス / 癌 / 遺伝子治療 / 腫瘍溶解性ウイルス

Outline of Final Research Achievements

Mammalian Reovirus (MRV) has important capacity that MRV show selective oncolytic activity in cancer cells. Currently, wild type T3D-C strain, which displays significant oncolytic activity, is developed as viral oncolytic agent. We generated recombinant RGD-MRV which has integrin-interactive RGD motif in MRV sigma1 protein to enable infection to MRV-resistant cancer cells via MRV receptor independent manner. This RGD-MRV exhibited enhanced infectivity and oncolysis of reovirus-resistant cancer cell. We generated various RGD-MRV variants which possessed multiple RGD motif, but not positive synergistic effect was observed. We examined the oncolytic activity of RGD-MRV to tumour in mice, but there were no significant differences in the oncolytic effect between RGD-MRV and wild-type MRV. That was, particular cancer cells resistant to infection of wild-type MRV transformed to be sensitive when the cells established tumour under mice skin.

Free Research Field

ウイルス学